PharmCube

We're a China-based data & media company dedicated to unearthing the trends in the Chinese pharmaceutical industry.

#Pharma #Biotech #Investment #Innovation

[PharmCube @pharmcube]

Bristol Myers Squibb and Hengrui Pharma have announced the second-largest pharma cooperation agreement (and China’s second-largest pharma deal overall)

[PharmCube @pharmcube]

find the link in official website to download the full reports：https://t.co/qWb7TqGUlL

[PharmCube @pharmcube]

Here are the 25 drug targets you should keep an eye on

✅𝗡𝗲𝘄 𝗧𝗮𝗿𝗴𝗲𝘁𝘀
✅𝗣𝗼𝗖 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻
✅𝗧𝗮𝗿𝗴𝗲𝘁 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝘀
✅𝗡𝗲𝘄 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀

[PharmCube @pharmcube]

China is driving small interfering RNA (siRNA) licensing activity, accounting for 40% of global transactions this decade. In line with this trend, the country has recently experienced a surge in overseas demand for its siRNA therapies, mainly driven by Big Pharma.

[PharmCube @pharmcube]

🔥🔥In just two weeks, you can experience PharmCube’s China-native pharmaceutical databases firsthand at our ChinaBio Partnering Forum booth

[PharmCube @pharmcube]

📈Last year saw massive investments into the Nav1.8 drug target. This year it could be a surge in licensing deals

[PharmCube @pharmcube]

Stop wasting time on manual data verification. Turn your AI from an unreliable intern into a senior analyst with the PharmCube MCP engine.

👉Contact me for details on how to start a free trial

[PharmCube @pharmcube]

❓Evaluate your drug target or company of interest in minutes. Why spend hours on manual research or risk being misled by an unreliable AI?

🤩Introducing PharmCube MCP (Model Context Protocol) — the data navigator linking Agentic AI with our authoritative pharma databases.

[PharmCube @pharmcube]

✅ Speed: Move from half a day of manual research to a 5-minute precise draft.
✅ Traceability: Every data point includes a verifiable evidence chain.
✅ 360° View: Smart cross-linking across Pipelines, Trials, M&A/Financing, and Regulatory data.

[PharmCube @pharmcube]

Although no one can match Pfizer’s USD 43b purchase of Seagen, Gilead Sciences has so far committed USD 26b to the ADC field following its acquisition of Tubulis GmbH for up to USD 5b (Gilead’s second, and the fifth-largest overall M&A transaction for an ADC company)

[PharmCube @pharmcube]

4⃣Beyond the Roadshow: Deep-dive into the NewCo model and long-term technical platform collaborations that are redefining 2026 deal-making.

[PharmCube @pharmcube]

🔥🔥40 high-potential Chinese drug assets will be presented on stage on May 20–21 at this year’s Healthcare Investment and Financing Transaction Conference in Shanghai.

register to attend：https://t.co/OrPxD6Xkds

[PharmCube @pharmcube]

3⃣High-Level Networking: Connect with confirmed leaders from Lilly, Roche, Sanofi, GSK, Pfizer, and Novartis, alongside top-tier healthcare VCs.

[PharmCube @pharmcube]

2⃣Early-Stage Alpha: Focus on Clinical Phase II and earlier — the critical window for securing strategic positions in globally promising projects.

[PharmCube @pharmcube]

Why this is a must-attend for BD & Investment Leaders:

1⃣Data-Driven Selection: We leverage PharmCube’s proprietary global pipeline tracking to filter for high-value assets in CGT, NDCs, Oligonucleotides, and Multispecifics.

[PharmCube @pharmcube]

The third-largest China-outbound AI drug discovery deal has been announced by Insilico Medicine and metabolic disease expert Eli Lilly and Company, with a value of up to USD 2.75b, as the companies upgrade a 2025 collaboration worth USD 99m

[PharmCube @pharmcube]

Free trial: https://t.co/jVl1OgCXWP

[PharmCube @pharmcube]

Eli Lilly and Company has just closed the largest deal in the OX2R agonist space, acquiring neuroscience specialist Centessa Pharmaceuticals along with its OX2R portfolio for USD 7.8b (USD 6.3b upfront).

[PharmCube @pharmcube]

Follow PharmCube for more insights into the Chinese and global pharma industries, or click the link in the comments to start a free trial of our databases and conduct your own market analyses.

[PharmCube @pharmcube]

Free trial:
https://t.co/jVl1OgCXWP

[PharmCube @pharmcube]

With the potential to treat thousands of rare diseases using a single drug, tRNA therapies represent the third wave of RNA therapeutics. This technology is now entering the clinic for the first time, with Alltrna receiving approval to advance AP003 to human trials in Australia